Recently, Brunner et al. (2018), in a phase II trial, showed that 67% of AML patients with adverse karyotype and 75% of those with TP53 mutations achieved complete remission with the use of alisertib [207]. This evidence concerns the gene TP53 and acute myeloid leukemia.